Clinical Trial Results:
A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopinavir (LPV)/Ritonavir (RTV)/1400mg/533mg/133mg Twice Daily (BID) and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-infected Adults Experiencing Virological Failure
Summary
|
|
EudraCT number |
2004-003827-10 |
Trial protocol |
ES DE IT GB |
Global completion date |
30 Apr 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 Feb 2016
|
First version publication date |
08 Nov 2014
|
Other versions |
|
Summary report(s) |
APV102002-Clinical-Study-Result-Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.